Application of CSRP2 serving as marker for evaluating prognostic risk of adult B-ALL patients

A prognostic and risk technology, applied in the field of biomedicine, can solve problems such as patient recurrence

Active Publication Date: 2016-09-28
北京旌准医疗科技有限公司
View PDF6 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is worth noting that some of the standard-risk patients still relapsed, suggesting that the current risk stratification still needs to be refined, so the discovery and verification of new prognostic molecular markers is necessary for more accurate risk stratification , and may provide therapeutic targets

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CSRP2 serving as marker for evaluating prognostic risk of adult B-ALL patients
  • Application of CSRP2 serving as marker for evaluating prognostic risk of adult B-ALL patients
  • Application of CSRP2 serving as marker for evaluating prognostic risk of adult B-ALL patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1. Low CSRP2 expression—a potential independent risk factor for adult B-lineage acute lymphoblastic leukemia

[0031] 1. Research objects and methods

[0032] (1) Research object

[0033] 1. Inclusion criteria

[0034] A total of 83 patients with newly diagnosed B-ALL in Peking University People's Hospital from December 2008 to September 2015 were collected as the research group. Inclusion criteria: ① age ≥ 14 years old; ② meet the B-ALL standard diagnosis (refer to WHO classification criteria for precursor B and T cell tumors); ③ all newly diagnosed, without any relevant treatment. Another 43 healthy donors of hematopoietic stem cell transplantation were selected as the control group, and the inclusion criteria were: ① age ≥ 14 years old; ② blood system diseases were excluded by examination. This study was approved by the ethics committee of our hospital. The patient or the patient's guardian (if the patient's age is <18 years old) signed the informed conse...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of CSRP2 serving as a marker for evaluating prognostic risk of adult B-ALL patients. The application provided by the invention is particularly the application of a detection substance for detecting mRNA coding CSRP2 protein in preparation of a product for evaluating the prognostic risk of patients suffering acute b lymphoblastic leukemia or application in evaluation of the prognostic risk of the patients suffering acute b lymphoblastic leukemia. Experimental results prove that CSRP2 low expression may be the independent risk factor of the OS, EFS and RFS of an adult B-ALL patient and may be play important roles in hierarchical diagnosis and prognostic evaluation of B-ALL.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the application of CSRP2 as a marker for evaluating the prognosis of adult B-ALL patients. Background technique [0002] B-lineage acute lymphoblastic leukemia (ALL) is the most common type of ALL in adults, and progress in risk stratification and treatment has significantly improved the prognosis of patients, but the recurrence rate of adult B-ALL is high, and the overall prognosis is still poor , long-term survival is only 30% -40%. Current risk stratification divides patients into standard risk and high risk according to age, initial white blood cell count, karyotype, central nervous system involvement, and response to initial treatment [Burke PW, Douer D. Acute lymphoblastic leukemia in adolescents and young adults . Acta Haematol. 2014;132:264–73.]. However, it is worth noting that some of the standard-risk patients still relapsed, suggesting that the current risk stratification st...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/118C12Q2600/158
Inventor 阮国瑞刘开彦黄晓军王树娟王卫敏卢文艺冯永怀张加敏姚秋妹周娇
Owner 北京旌准医疗科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap